Trials / Completed
CompletedNCT05469685
Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication
Efficacy and Safety of Vonoprazan- Amoxicillin Dual Therapy for Helicobacter Pylori Eradication : a Prospective, Multicenter, Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 914 (actual)
- Sponsor
- Nanjing First Hospital, Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the Efficacy and Safety of Vonoprazan- amoxicillin dual therapy for Helicobacter Pylori eradication
Detailed description
This study intends to select the patients with Hp infection in 11 tertiary hospitals across our country, and randomly give the two therapies to compare the eradication rate, compliance, the rate of adverse events, so as to provide some advices for the selection of appropriate eradication therapy, then collect an efficient, convenient and safe therapy for patients with H.pylori infection. Before receiving the treatment plan, general information and relevant medical history of the subjects were collected through electronic questionnaires.The experimental data will be collected and recorded through follow-up by phone or WeChat during the experiment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vonoprazan | Potassium-competitive acid blocker |
| DRUG | Amoxicillin | Antibiotic for H. pylori eradication |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2023-08-31
- Completion
- 2023-09-30
- First posted
- 2022-07-22
- Last updated
- 2024-06-13
Locations
10 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05469685. Inclusion in this directory is not an endorsement.